舒尼替尼对胃肠道间质瘤患者二线治疗的临床观察

Clinical observation of sunitinib as second-line treatment for patients with gastrointestinal stromal tumor

目的探讨二线药物舒尼替尼治疗胃肠道间质瘤(GIST)的疗效及安全性。方法回顾性分析经病理组织和免疫组化确诊的GIST患者32例,所有的患者均用二线药物舒尼替尼治疗,37.5 mg·d^(-1)口服,连续给药服用。观察评估舒尼替尼的不良反应及患者的生存时间。结果舒尼替尼治疗GIST的不良反应轻微,且均可控制。32例患者接受舒尼替尼治疗的时间为3~72个月,中位治疗时间为24个月。获得完全缓解(CR)1例,部分缓解(PR)7例,稳定期(SD)16例,进展(PD)8例,有效率25.0%,疾病控制率75.0%。32例患者中,中位随访时间为96周,中位无进展生存期(PFS)为55周,中位总生存时间(OS)为96周。结论舒尼替尼治疗伊马替尼耐药进展的GIST疗效可靠,不良反应轻微,安全可控。

Objective To investigate the efficacy and toxicity profile of sunitinib malate in treating gastrointestinal stromal tumors （GIST）. Methods We retrospectively reviewed clinical data from 32 patients with a histopathologically and immunohistochemically confirmed diagnosis of GIST who were referred to the general surgery department. All patients were treated with sunitinib as second linetreatment 37. 5 mg · d ^-1 on CDD （continuous daily dosing） schedule. Toxicity of sunitinib therapy and patients？ survival time were an-alyzed. Results The most common adverse events of sunitinib therapy were slight and safe. The duration of sunitinib therapy was 3 to72 months in our study and the median treatment duration was 18 months. Of the 32 patients, clinical response （ CR） was observed in 1 patient,partial response （PR） in 7 patients,stable disease （ SD） in 16 patients, and progressive disease （ PD） in 8 patients, with aclinical benefit rate of 25. 0% and disease control rate of 75. 0%. The median period of follow-up was 96 weeks,median progression-free survival （PFS） and overall survival （OS） were 55 weeks and 96 weeks,respectively. Conclusions Sunitinib therapy is accepta-ble and safe with mild adverse reactions for patients with advanced GIST intolerant to imatinib therapy.